Ticker	Volume	Price	Price Delta
DJIA	12,454.80	-74.92	-0.60%
S&P 500	1,317.82	-2.86	-0.22%
Nasdaq	2,837.53	-1.85	-0.07%

Ticker

Volume

Price

Price Delta

DJIA

12,454.80

-74.92

-0.60%

S&P 500

1,317.82

-2.86

-0.22%

Nasdaq

2,837.53

-1.85

-0.07%

Ticker	Volume	Price	Price Delta
STOXX 50	2,161.87	+5.35	0.25%
FTSE 100	5,351.53	+1.48	0.03%
DAX	6,339.94	+24.05	0.38%

Ticker

Volume

Price

Price Delta

STOXX 50

2,161.87

+5.35

0.25%

FTSE 100

5,351.53

+1.48

0.03%

DAX

6,339.94

+24.05

0.38%

Ticker	Volume	Price	Price Delta
Nikkei	8,580.39	+17.01	0.20%
TOPIX	722.11	-0.14	-0.02%
Hang Seng	18,713.40	+47.01	0.25%

Ticker

Volume

Price

Price Delta

Nikkei

8,580.39

+17.01

0.20%

TOPIX

722.11

-0.14

-0.02%

Hang Seng

18,713.40

+47.01

0.25%

Roche’s Herceptin Heart Risk Higher for Older Women, Study Says

By Naomi Kresge - 2011-08-09T23:30:00Z

Roche Holding AG (ROG)’s cancer drug Herceptin poses a bigger risk of heart problems for elderly patients than for the younger women usually recruited in clinical trials, researchers said in a study published today in the journal Annals of Oncology.

The study reviewed records for 45 women between the ages of 70 and 92, and it’s the first to assess the Roche drug’s heart risks specifically for elderly patients, researchers said.

To contact the reporter on this story: Naomi Kresge in Zurich at nkresge@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net